img

Global PD-1 and PD-L1 Monoclonal Antibody Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global PD-1 and PD-L1 Monoclonal Antibody Market Research Report 2024

According to Mr Accuracy reports’s new survey, global PD-1 and PD-L1 Monoclonal Antibody market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole PD-1 and PD-L1 Monoclonal Antibody market research.
Key manufacturers engaged in the PD-1 and PD-L1 Monoclonal Antibody industry include Merk, Bristol-Myers Squibb Company, Roche, Pfizer, AstraZeneca, Junshi Biosciences, Innovent, Hengrui and BeiGene, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of PD-1 and PD-L1 Monoclonal Antibody were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole PD-1 and PD-L1 Monoclonal Antibody market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global PD-1 and PD-L1 Monoclonal Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Merk
Bristol-Myers Squibb Company
Roche
Pfizer
AstraZeneca
Junshi Biosciences
Innovent
Hengrui
BeiGene
Alphamab Oncology
Cstone
Akeso
Segment by Type
PD-1
PD-L1

Segment by Application


Lung Cancer
Liver Cancer
Esophageal Cancer
Gastric Cancer
Nasopharyngeal Carcinoma
Head and Neck Cancer
Other

Consumption by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The PD-1 and PD-L1 Monoclonal Antibody report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 PD-1 and PD-L1 Monoclonal Antibody Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Monoclonal Antibody
1.2 PD-1 and PD-L1 Monoclonal Antibody Segment by Type
1.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2024-2034)
1.2.2 PD-1
1.2.3 PD-L1
1.3 PD-1 and PD-L1 Monoclonal Antibody Segment by Application
1.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Value by Application: (2024-2034)
1.3.2 Lung Cancer
1.3.3 Liver Cancer
1.3.4 Esophageal Cancer
1.3.5 Gastric Cancer
1.3.6 Nasopharyngeal Carcinoma
1.3.7 Head and Neck Cancer
1.3.8 Other
1.4 Global PD-1 and PD-L1 Monoclonal Antibody Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue 2018-2034
1.4.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales 2018-2034
1.4.3 Global PD-1 and PD-L1 Monoclonal Antibody Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 PD-1 and PD-L1 Monoclonal Antibody Market Competition by Manufacturers
2.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Manufacturers (2018-2023)
2.3 Global PD-1 and PD-L1 Monoclonal Antibody Average Price by Manufacturers (2018-2023)
2.4 Global PD-1 and PD-L1 Monoclonal Antibody Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Product Type & Application
2.7 PD-1 and PD-L1 Monoclonal Antibody Market Competitive Situation and Trends
2.7.1 PD-1 and PD-L1 Monoclonal Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Monoclonal Antibody Players Market Share by Revenue
2.7.3 Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PD-L1 Monoclonal Antibody Retrospective Market Scenario by Region
3.1 Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global PD-1 and PD-L1 Monoclonal Antibody Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2018-2034
3.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2018-2023
3.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region: 2024-2034
3.3 Global PD-1 and PD-L1 Monoclonal Antibody Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2018-2034
3.3.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2018-2023
3.3.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2024-2034
3.4 North America PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country
3.4.1 North America PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2034)
3.4.3 North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2034)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country
3.5.1 Europe PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2034)
3.5.3 Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2034)
3.6.3 Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2034)
3.7.3 Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2034)
3.8.3 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2034)
4.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2018-2023)
4.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Type (2024-2034)
4.1.3 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2034)
4.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2018-2034)
4.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2018-2023)
4.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Type (2024-2034)
4.2.3 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2034)
4.3 Global PD-1 and PD-L1 Monoclonal Antibody Price by Type (2018-2034)
5 Segment by Application
5.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2034)
5.1.1 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2018-2023)
5.1.2 Global PD-1 and PD-L1 Monoclonal Antibody Sales by Application (2024-2034)
5.1.3 Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2034)
5.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2018-2034)
5.2.1 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2018-2023)
5.2.2 Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Application (2024-2034)
5.2.3 Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2018-2034)
5.3 Global PD-1 and PD-L1 Monoclonal Antibody Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Merk
6.1.1 Merk Corporation Information
6.1.2 Merk Description and Business Overview
6.1.3 Merk PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merk PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.1.5 Merk Recent Developments/Updates
6.2 Bristol-Myers Squibb Company
6.2.1 Bristol-Myers Squibb Company Corporation Information
6.2.2 Bristol-Myers Squibb Company Description and Business Overview
6.2.3 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.2.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.5.4 AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Junshi Biosciences
6.6.1 Junshi Biosciences Corporation Information
6.6.2 Junshi Biosciences Description and Business Overview
6.6.3 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.6.5 Junshi Biosciences Recent Developments/Updates
6.7 Innovent
6.6.1 Innovent Corporation Information
6.6.2 Innovent Description and Business Overview
6.6.3 Innovent PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Innovent PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.7.5 Innovent Recent Developments/Updates
6.8 Hengrui
6.8.1 Hengrui Corporation Information
6.8.2 Hengrui Description and Business Overview
6.8.3 Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Hengrui PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.8.5 Hengrui Recent Developments/Updates
6.9 BeiGene
6.9.1 BeiGene Corporation Information
6.9.2 BeiGene Description and Business Overview
6.9.3 BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.9.4 BeiGene PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.9.5 BeiGene Recent Developments/Updates
6.10 Alphamab Oncology
6.10.1 Alphamab Oncology Corporation Information
6.10.2 Alphamab Oncology Description and Business Overview
6.10.3 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.10.5 Alphamab Oncology Recent Developments/Updates
6.11 Cstone
6.11.1 Cstone Corporation Information
6.11.2 Cstone PD-1 and PD-L1 Monoclonal Antibody Description and Business Overview
6.11.3 Cstone PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Cstone PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.11.5 Cstone Recent Developments/Updates
6.12 Akeso
6.12.1 Akeso Corporation Information
6.12.2 Akeso PD-1 and PD-L1 Monoclonal Antibody Description and Business Overview
6.12.3 Akeso PD-1 and PD-L1 Monoclonal Antibody Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Akeso PD-1 and PD-L1 Monoclonal Antibody Product Portfolio
6.12.5 Akeso Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PD-L1 Monoclonal Antibody Industry Chain Analysis
7.2 PD-1 and PD-L1 Monoclonal Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PD-L1 Monoclonal Antibody Production Mode & Process
7.4 PD-1 and PD-L1 Monoclonal Antibody Sales and Marketing
7.4.1 PD-1 and PD-L1 Monoclonal Antibody Sales Channels
7.4.2 PD-1 and PD-L1 Monoclonal Antibody Distributors
7.5 PD-1 and PD-L1 Monoclonal Antibody Customers
8 PD-1 and PD-L1 Monoclonal Antibody Market Dynamics
8.1 PD-1 and PD-L1 Monoclonal Antibody Industry Trends
8.2 PD-1 and PD-L1 Monoclonal Antibody Market Drivers
8.3 PD-1 and PD-L1 Monoclonal Antibody Market Challenges
8.4 PD-1 and PD-L1 Monoclonal Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global PD-1 and PD-L1 Monoclonal Antibody Market Competitive Situation by Manufacturers in 2024
Table 4. Global PD-1 and PD-L1 Monoclonal Antibody Sales (Units) of Key Manufacturers (2018-2023)
Table 5. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Manufacturers (2018-2023)
Table 6. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market PD-1 and PD-L1 Monoclonal Antibody Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of PD-1 and PD-L1 Monoclonal Antibody, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Product Type & Application
Table 12. Global Key Manufacturers of PD-1 and PD-L1 Monoclonal Antibody, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PD-1 and PD-L1 Monoclonal Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Monoclonal Antibody as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023) & (Units)
Table 18. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2018-2023)
Table 19. Global PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2024-2034) & (Units)
Table 20. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2024-2034)
Table 21. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2018-2023)
Table 23. Global PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2024-2034)
Table 25. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 27. North America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2024-2034) & (Units)
Table 28. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 32. Europe PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2024-2034) & (Units)
Table 33. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2018-2023) & (Units)
Table 37. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales by Region (2024-2034) & (Units)
Table 38. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 42. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2024-2034) & (Units)
Table 43. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2018-2023) & (Units)
Table 47. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales by Country (2024-2034) & (Units)
Table 48. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global PD-1 and PD-L1 Monoclonal Antibody Sales (Units) by Type (2018-2023)
Table 51. Global PD-1 and PD-L1 Monoclonal Antibody Sales (Units) by Type (2024-2034)
Table 52. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2018-2023)
Table 53. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Type (2024-2034)
Table 54. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Type (2018-2023)
Table 55. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Type (2024-2034)
Table 56. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2018-2023)
Table 57. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Type (2024-2034)
Table 58. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2018-2023)
Table 59. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2024-2034)
Table 60. Global PD-1 and PD-L1 Monoclonal Antibody Sales (Units) by Application (2018-2023)
Table 61. Global PD-1 and PD-L1 Monoclonal Antibody Sales (Units) by Application (2024-2034)
Table 62. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2018-2023)
Table 63. Global PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Application (2024-2034)
Table 64. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Application (2018-2023)
Table 65. Global PD-1 and PD-L1 Monoclonal Antibody Revenue (US$ Million) by Application (2024-2034)
Table 66. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2018-2023)
Table 67. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Application (2024-2034)
Table 68. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2018-2023)
Table 69. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2024-2034)
Table 70. Merk Corporation Information
Table 71. Merk Description and Business Overview
Table 72. Merk PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Merk PD-1 and PD-L1 Monoclonal Antibody Product
Table 74. Merk Recent Developments/Updates
Table 75. Bristol-Myers Squibb Company Corporation Information
Table 76. Bristol-Myers Squibb Company Description and Business Overview
Table 77. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Bristol-Myers Squibb Company PD-1 and PD-L1 Monoclonal Antibody Product
Table 79. Bristol-Myers Squibb Company Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Roche PD-1 and PD-L1 Monoclonal Antibody Product
Table 84. Roche Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Pfizer PD-1 and PD-L1 Monoclonal Antibody Product
Table 89. Pfizer Recent Developments/Updates
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. AstraZeneca PD-1 and PD-L1 Monoclonal Antibody Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Junshi Biosciences Corporation Information
Table 96. Junshi Biosciences Description and Business Overview
Table 97. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Junshi Biosciences PD-1 and PD-L1 Monoclonal Antibody Product
Table 99. Junshi Biosciences Recent Developments/Updates
Table 100. Innovent Corporation Information
Table 101. Innovent Description and Business Overview
Table 102. Innovent PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Innovent PD-1 and PD-L1 Monoclonal Antibody Product
Table 104. Innovent Recent Developments/Updates
Table 105. Hengrui Corporation Information
Table 106. Hengrui Description and Business Overview
Table 107. Hengrui PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Hengrui PD-1 and PD-L1 Monoclonal Antibody Product
Table 109. Hengrui Recent Developments/Updates
Table 110. BeiGene Corporation Information
Table 111. BeiGene Description and Business Overview
Table 112. BeiGene PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. BeiGene PD-1 and PD-L1 Monoclonal Antibody Product
Table 114. BeiGene Recent Developments/Updates
Table 115. Alphamab Oncology Corporation Information
Table 116. Alphamab Oncology Description and Business Overview
Table 117. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Alphamab Oncology PD-1 and PD-L1 Monoclonal Antibody Product
Table 119. Alphamab Oncology Recent Developments/Updates
Table 120. Cstone Corporation Information
Table 121. Cstone Description and Business Overview
Table 122. Cstone PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Cstone PD-1 and PD-L1 Monoclonal Antibody Product
Table 124. Cstone Recent Developments/Updates
Table 125. Akeso Corporation Information
Table 126. Akeso Description and Business Overview
Table 127. Akeso PD-1 and PD-L1 Monoclonal Antibody Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 128. Akeso PD-1 and PD-L1 Monoclonal Antibody Product
Table 129. Akeso Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. PD-1 and PD-L1 Monoclonal Antibody Distributors List
Table 133. PD-1 and PD-L1 Monoclonal Antibody Customers List
Table 134. PD-1 and PD-L1 Monoclonal Antibody Market Trends
Table 135. PD-1 and PD-L1 Monoclonal Antibody Market Drivers
Table 136. PD-1 and PD-L1 Monoclonal Antibody Market Challenges
Table 137. PD-1 and PD-L1 Monoclonal Antibody Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1 and PD-L1 Monoclonal Antibody
Figure 2. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Type in 2024 & 2034
Figure 4. PD-1 Product Picture
Figure 5. PD-L1 Product Picture
Figure 6. Global PD-1 and PD-L1 Monoclonal Antibody Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global PD-1 and PD-L1 Monoclonal Antibody Market Share by Application in 2024 & 2034
Figure 8. Lung Cancer
Figure 9. Liver Cancer
Figure 10. Esophageal Cancer
Figure 11. Gastric Cancer
Figure 12. Nasopharyngeal Carcinoma
Figure 13. Head and Neck Cancer
Figure 14. Other
Figure 15. Global PD-1 and PD-L1 Monoclonal Antibody Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global PD-1 and PD-L1 Monoclonal Antibody Market Size (2018-2034) & (US$ Million)
Figure 17. Global PD-1 and PD-L1 Monoclonal Antibody Sales (2018-2034) & (Units)
Figure 18. Global PD-1 and PD-L1 Monoclonal Antibody Average Price (US$/Unit) & (2018-2034)
Figure 19. PD-1 and PD-L1 Monoclonal Antibody Report Years Considered
Figure 20. PD-1 and PD-L1 Monoclonal Antibody Sales Share by Manufacturers in 2024
Figure 21. Global PD-1 and PD-L1 Monoclonal Antibody Revenue Share by Manufacturers in 2024
Figure 22. The Global 5 and 10 Largest PD-1 and PD-L1 Monoclonal Antibody Players: Market Share by Revenue in 2024
Figure 23. PD-1 and PD-L1 Monoclonal Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 24. Global PD-1 and PD-L1 Monoclonal Antibody Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 25. North America PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 26. North America PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 27. U.S. PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 28. Canada PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. Europe PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 30. Europe PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 31. Germany PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. France PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. U.K. PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 34. Italy PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 35. Russia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Region (2018-2034)
Figure 37. Asia Pacific PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Region (2018-2034)
Figure 38. China PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Japan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. South Korea PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. India PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Australia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Taiwan PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Indonesia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 45. Thailand PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 46. Malaysia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Philippines PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Latin America PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 49. Latin America PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 50. Mexico PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 51. Brazil PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 52. Argentina PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Sales Market Share by Country (2018-2034)
Figure 54. Middle East & Africa PD-1 and PD-L1 Monoclonal Antibody Revenue Market Share by Country (2018-2034)
Figure 55. Turkey PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 56. Saudi Arabia PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 57. U.A.E PD-1 and PD-L1 Monoclonal Antibody Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 58. Global Sales Market Share of PD-1 and PD-L1 Monoclonal Antibody by Type (2018-2034)
Figure 59. Global Revenue Market Share of PD-1 and PD-L1 Monoclonal Antibody by Type (2018-2034)
Figure 60. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Type (2018-2034)
Figure 61. Global Sales Market Share of PD-1 and PD-L1 Monoclonal Antibody by Application (2018-2034)
Figure 62. Global Revenue Market Share of PD-1 and PD-L1 Monoclonal Antibody by Application (2018-2034)
Figure 63. Global PD-1 and PD-L1 Monoclonal Antibody Price (US$/Unit) by Application (2018-2034)
Figure 64. PD-1 and PD-L1 Monoclonal Antibody Value Chain
Figure 65. PD-1 and PD-L1 Monoclonal Antibody Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed